KRAS c.35G>C detected. What does this mean

Understanding Your KRAS c.35G>C Mutation

I'm glad you're asking about this finding. Let me explain what this mutation means in the context of sigmoid cancer.

What This Mutation Is

KRAS c.35G>C is a specific genetic change in your cancer cells. Here's what's happening:

• KRAS is a gene that normally acts like a "growth brake" in cells—it controls whether cells divide and grow
• c.35G>C means that at position 35 in the KRAS gene, the genetic code changed from a "G" (guanine) to a "C" (cytosine)
• This particular change typically results in what's called a G12A mutation at the protein level—one of the most common KRAS mutations found in colorectal cancers

Why This Matters for Sigmoid Cancer

This is an important finding because:

• KRAS mutations are common in colorectal cancer, occurring in approximately 40-50% of cases
• When KRAS is mutated, it gets "stuck" in an "on" position, constantly telling cells to grow and divide—even when they shouldn't
• This mutation typically makes cancer cells more aggressive and can affect treatment options

How Doctors Think About KRAS Mutations

Oncologists evaluate KRAS mutations because they influence treatment decisions:

1. Traditional chemotherapy (like 5-fluorouracil or FOLFOX regimens) may still be effective, but KRAS-mutant tumors sometimes respond differently than KRAS-wild-type (non-mutated) tumors

2. Targeted therapies have historically been limited for KRAS mutations, but this landscape is changing rapidly with newer drugs

3. Immunotherapy (checkpoint inhibitors) effectiveness may depend on other tumor characteristics alongside KRAS status

What Treatment Options Generally Exist

According to NCCN Guidelines for Colorectal Cancer, patients with KRAS mutations may be considered for:

• Standard chemotherapy combinations as first-line treatment
• Newer KRAS-targeted therapies (like sotorasib or adagrasib) in certain situations—these are FDA-approved drugs that specifically target KRAS G12C mutations, though your specific G12A variant may have different options
• Combination approaches pairing chemotherapy with other targeted agents
• Clinical trials testing novel KRAS-targeting strategies

The American Cancer Society emphasizes that KRAS status is increasingly important for treatment planning in colorectal cancer, and testing for this mutation is now standard practice.

Critical Questions to Ask Your Oncologist

Since your specific situation requires your doctor's complete evaluation, here are targeted questions:

1. "Does my specific KRAS mutation (G12A) qualify me for any of the newer KRAS-targeted drugs like sotorasib or adagrasib?" (These work best for G12C mutations, but your doctor will know what's available for G12A)

2. "What is my complete tumor profile?" (Your doctor should consider other factors like MSI/MMR status, which might open immunotherapy options)

3. "What is your recommended first-line treatment approach for my KRAS-mutant sigmoid cancer, and why?"

4. "Are there any clinical trials I should consider that specifically target KRAS mutations?"

5. "How will you monitor my response to treatment, and what would trigger a change in strategy?"

Important Context

Having a KRAS mutation doesn't mean your cancer is untreatable—it means your oncologist has specific information to guide treatment selection. Many patients with KRAS-mutant colorectal cancers respond well to appropriate therapy.

According to NCCN Colorectal Cancer Guidelines, the presence of KRAS mutation should be integrated with other tumor characteristics (stage, location, MSI status, performance status) to determine the optimal treatment plan.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.